Propranolol, a very promising treatment for ulceration in infantile hemangiomas: A study of 20 cases with matched historical controls - 10/08/11
, Ingrid Mathilde van Beynum, MD b, Leonardus Jan Schultze Kool, PhD c, Peter Cornelius Maria van de Kerkhof, PhD a, Marcus Henricus Wilhelmus Andreas Wijnen, PhD d, Catharina Joanna Maria van der Vleuten, PhD a
Correspondence to: Denise Josephina Johanna Hermans, MD, René Descartesdreef 1, 6500 HB, Nijmegen, The Netherlands.Abstract |
Background |
Ulceration is a common but poorly understood complication of infantile hemangiomas (IH) that is difficult to control.
Objective |
To investigate the possible role of monotherapy with propranolol for ulcerating IH.
Methods |
Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3.5 months; standard error of the mean: 0.4). After cardiac screening, propranolol was administered in a progressive schedule to 2 to 2.5 mg/kg per day, divided in 3 doses. Blood pressure, heart rate, and fasting glucose levels were monitored during the first 3 days in hospital and, in the absence of complications, treatment was continued at home until the age of approximately 1 year. The 20 propranolol-treated patients were matched to patients from a historical control group, seen before the ‘propranolol era’. These matches were randomly made by using clinical pictures based on type, location and size of the IH, extent of ulceration, and age at the start of ulceration.
Results |
The time to complete healing from the onset of ulceration was significantly shorter for the propranolol-treated patients, compared with the control group (8.7 vs 22.4 weeks; t test: P < .015). In the propranolol group, a tendency to shorter ulceration duration was seen in patients starting propranolol at an earlier stage of disease.
Limitations |
The study was limited by the partially retrospective design and the small number of patients.
Conclusion |
Propranolol reduces the duration of ulceration in IH and seems to be more effective when started in an early phase. We propose propranolol as the treatment of first choice for ulcerating IH.
Le texte complet de cet article est disponible en PDF.Key words : beta-blocker, infantile hemangioma, infants, propranolol, ulceration
Abbreviations used : IH, PDL, SEM
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 64 - N° 5
P. 833-838 - mai 2011 Retour au numéro
Article précédent
- Propranolol for treatment of ulcerated infantile hemangiomas
- Mélanie Saint-Jean, Christine Léauté-Labrèze, Juliette Mazereeuw-Hautier, Nathalie Bodak, Dominique Hamel-Teillac, Ingrid Kupfer-Bessaguet, Jean-Philippe Lacour, Michaël Naouri, Pierre Vabres, Smail Hadj-Rabia, Jean-Michel Nguyen, Jean-François Stalder, Sébastien Barbarot, Groupe de Recherche Clinique en Dermatologie Pédiatrique
- Delayed treatment and continued growth of nonmelanoma skin cancer
- Murad Alam, Leonard H. Goldberg, Sirunya Silapunt, Erin S. Gardner, Sara S. Strom, Alfred W. Rademaker, David J. Margolis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?